Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
436 stopped studies mapped to Squamous Cell Carcinoma and descendants · 91% state a reason
Over the 436 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced… | N/A | withdrawn | Oct 28, 2019 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | Phase 1 / Phase 2 | terminated | Jun 1, 2020 | Ivan Litvinov | Inability to recruit patients/lack of funding | Enrollment / accrual |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in… | Phase 1 / Phase 2 | terminated | Oct 29, 2021 | NKGen Biotech, Inc. | Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best… | Other (stated, no rule matched) |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant,… | Phase 1 | terminated | Nov 10, 2020 | Washington University School of Medicine | Ipsen bought out Epizyme | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | Phase 2 | terminated | Nov 18, 2020 | MacroGenics | Based on internal review of safety data | Safety / toxicity |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122…(PANTHEoN) | Phase 1 | withdrawn | May 19, 2021 | Jennifer Choe | Funding | Funding |
| NCT02285543 | A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients | Phase 2 | terminated | Nov 7, 2014 | Shanghai Jiao Tong University School of Medicine | No new participants could be enrolled. | Enrollment / accrual |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before… | Phase 1 / Phase 2 | terminated | Aug 7, 2018 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03875053 | Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage… | N/A | withdrawn | Mar 14, 2019 | Barbara Ann Karmanos Cancer Institute | No accrual | Enrollment / accrual |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung…(ENSIGN) | Phase 2 | terminated | Jul 13, 2016 | Eric Bernicker, MD | Lack of funding | Funding |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04193293 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | Phase 1 / Phase 2 | terminated | Dec 10, 2019 | SecuraBio | The study was terminated due to low enrollment. | Enrollment / accrual |
| NCT05359692 | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or… | Phase 2 | withdrawn | May 4, 2022 | Incyte Biosciences International Sàrl | Business decision; no safety concerns | Safety / toxicity |
| NCT01755650 | Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies | Early Phase 1 | terminated | Dec 24, 2012 | Peter MacCallum Cancer Centre, Australia | 6 patients were recuited. Due to inability of the tracer to detect regions of interest… | Other (stated, no rule matched) |
| NCT04834349 | Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of… | Phase 2 | withdrawn | Apr 8, 2021 | M.D. Anderson Cancer Center | No participants were enrolled | Enrollment / accrual |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous… | Phase 2 | withdrawn | Sep 10, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant… | Phase 2 | terminated | Apr 11, 2019 | Stanford University | Difficulty with enrollment | Enrollment / accrual |
| NCT02524275 | Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the… | Phase 2 | terminated | Aug 14, 2015 | University of Nebraska | low enrollment | Enrollment / accrual |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | Phase 1 | withdrawn | Feb 15, 2023 | Baptist Health South Florida | PI is leaving institution prior to study opening for accrual. | Enrollment / accrual |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible… | Phase 1 / Phase 2 | terminated | Jul 1, 2008 | Genmab | The decision is based on company re-evaluation of indications to be pursued within SCCHN | Sponsor / business decision |
| NCT04922112 | Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado(OSA-HN) | N/A | withdrawn | Jun 10, 2021 | University of Colorado, Denver | Unable to find participants, no enrollment | Enrollment / accrual |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | — | terminated | Dec 30, 2020 | Aristotle University Of Thessaloniki | Due to COVID-19 | COVID-19 / pandemic |
| NCT03740100 | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of…(HNSCC) | Phase 2 | terminated | Nov 14, 2018 | M.D. Anderson Cancer Center | The trial was closed because the sponsor became insolvent. | Other (stated, no rule matched) |
| NCT01824823 | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous… | Phase 2 | terminated | Apr 5, 2013 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A… | Early Phase 1 | withdrawn | Feb 5, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Poor accrual | Enrollment / accrual |
| NCT02488629 | Study of SCB01A in Patient With Head and Neck Cancer | Phase 2 | terminated | Jul 2, 2015 | SynCore Biotechnology Co., Ltd. | not stated | Not stated |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT03522584 | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | May 11, 2018 | University of Washington | Terminated by the sponsor due to lack of efficacy in study treatment. | Efficacy / futility |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | Phase 2 | terminated | Feb 4, 2019 | Lung Cancer Group Cologne | Study-related difficulties faced with patient enrolment, no safety-related reasons | Safety / toxicity |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT04987996 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell… | Phase 2 | withdrawn | Aug 3, 2021 | Providence Health & Services | Study withdrawn due to lack of supply of one of the investigational agents. | Drug supply |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in… | Phase 3 | terminated | Jul 27, 2009 | SWOG Cancer Research Network | terminated at pre-planned futility analysis | Efficacy / futility |
| NCT05743777 | PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head…(PROMOTE-HN) | Phase 2 | withdrawn | Feb 24, 2023 | Canadian Cancer Trials Group | Company withdrew financial support | Funding |
| NCT02345330 | Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck… | Phase 2 | terminated | Jan 26, 2015 | OncoSec Medical Incorporated | Due to company resource constraints | Sponsor / business decision |
| NCT03823131 | Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and… | Phase 2 | terminated | Jan 30, 2019 | Chase Heaton, MD | Treatment Ineffective | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03802058 | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | Phase 2 | terminated | Jan 14, 2019 | Wuhan University | The study was halted because enrollment was too slow | Enrollment / accrual |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients… | Phase 1 | withdrawn | Feb 2, 2022 | Rakuten Medical, Inc. | Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled. | Enrollment / accrual |
| NCT04110249 | Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and… | N/A | terminated | Oct 1, 2019 | Roswell Park Cancer Institute | equipment issues | Other (stated, no rule matched) |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With… | Phase 1 | withdrawn | Apr 11, 2011 | Fox Chase Cancer Center | Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients. | Enrollment / accrual |
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous… | Phase 2 | terminated | Aug 21, 2017 | Celldex Therapeutics | Sponsor decision based on emerging risk-benefit profile | Sponsor / business decision |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Nov 2, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment, Innovent Biologics has decided not to… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 8, 2024source: clinicaltrials